Long-Term Follow Up of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT).
Mohamed L. Sorror(University of Washington Medical Center), David G. Maloney(Fred Hutch Cancer Center), Jerry Radich(University of Washington), Benedetto Bruno(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Dietger Niederwieser(Leipzig University of Applied Sciences), Thomas R. Chauncey(City Of Hope National Medical Center), Amelia Langston(CancerCare Manitoba), Barry E. Storer(City Of Hope National Medical Center), Brenda M. Sandmaier(University of Washington), Rainer Storb(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Peter A. McSweeney(Mesoblast (United States)), Edward Agura(Baylor University), Karl G. Blume(City Of Hope National Medical Center), Michael B. Maris(Colorado Blood Cancer Institute), José F. Leis(Mayo Clinic), Michael A. Pulsipher(Primary Children's Hospital), James C. Wade(Medizinische Hochschule Hannover), Judith A. Shizuru(Stanford University)
Cited by 3
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k